ESC Congress coverages: The interventional cardiology perspective

55 results

Duration of DAPT in ACS: The DUAL-ACS Trial

31 Aug 2025

Ali Nazmi Calik interviews David Newby on the landmark DUAL-ACS trial results he presented at ESC Congress 2025 in Madrid.

The trial compared 3 months versus 12 months of dual antiplatelet therapy (DAPT) after myocardial infarction in an all-comer population. Findings suggest that shorter therapy may offer better...

Author

Ali Nazmi Calik

Author

David Newby

The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation

01 Sep 2025

Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.

Author

Chiara De Biase

DOUBLE-CHOICE: Anesthesia strategies and self-expanding valve types for TAVI

29 Aug 2025

Fresh from his DOUBLE-CHOICE trial presentation at ESC Congress 2025 in Madrid, Mohamed Abdel-Wahab joins Yohei Ohno to discuss the key takeaways.

This two-by-two factorial randomised trial in patients undergoing TAVI compared a minimalist strategy using only local anesthesia with the standard of care, as well as two...

Author

Yohei Ohno

Author

Mohamed Abdel-Wahab

PCRonline @ ESC Congress 2025: the interventional cardiology perspective!

26 Jul 2025

Stay updated with the latest in interventional cardiology at #ESCCongress 2025!

2024 ESC Guidelines: Peripheral arterial and aortic diseases - Focus on Peripheral Arterial Diseases

09 Sep 2024

The 2024 ESC Guidelines for aortic diseases, merged with peripheral arterial disease guidelines, update prior guidance and emphasize atherosclerotic conditions. In this article, Antoine Sauguet summarizes the content related to peripheral arterial diseases.

Author

Antoine Sauguet

TRIGISTRY: Benefit of isolated surgical valve repair or replacement for functional tricuspid regurgitation and long-term outcomes stratified by the TRI-SCORE

31 Aug 2024

Alex Sticchi provides his take on the TRIGISTRY study presented by Julien Dreyfus at the ESC Congress 2024 in London.

Simultaneous publication in European Heart Journal, ehae578

Author

Alessandro Sticchi

IVORY FINALE study: Low-dose interleukin-2 for the reduction of vascular inflammation in ACS - Clinical outcomes and follow-up

31 Aug 2024

Aaysha Cader interviews Rouchelle Sriranjan about the results of the IVORY and IVORY 2 trials which she presented at the ESC Congress 2024 in London.

The trials examined low-dose interleukin-2 therapy to reduce arterial inflammation in acute coronary syndrome patients. The study found a 7.7% reduction in arterial inflammation...

Author

Aaysha Cader

Author

Rouchelle Sriranjan

REC-CAGEFREE I - Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of de novo coronary artery lesions

08 Sep 2024

Mirvat Alasnag provides her take on REC-CAGEFREE I, a multicenter, non-inferiority trial presented at the ESC Congress 2024 in London.

Author

Mirvat Alasnag

INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes

03 Sep 2024

Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.

Author

Daniele Giacoppo

OCCUPI - Optical coherence tomography-guided coronary intervention in patients with complex lesions

03 Sep 2024

Alex Sticchi provides his take on the OCCUPI trial presented by Kim Byeong-Keuk at the ESC Congress 2024 in London.

Author

Alessandro Sticchi